🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Procter & Gamble Health Limited PGHL NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.pghealthindia.com

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.

READ MORE ›
₹6,056.00
+7.68% 1Y

Market & Price

Market Cap
₹10,052.59 Cr
Current Price
₹6,056.00
High / Low (52W)
₹6,389.44 / ₹4,778.60
Beta
0.15

Valuation

Stock P/E
30.77
Industry PE
37.60
Forward P/E
31.94
PEG Ratio
-
Book Value
₹373.35
Price to Book
16.22
P/S
7.14
EV/EBITDA
21.63
Dividend Yield
2.56%

Profitability & Returns

ROCE
76.81%
ROE
61.59%
ROA
33.10%
Profit Margin
23.22%
Op Margin
34.94%
EPS (Latest Qtr)
₹56.99
EPS (TTM)
₹196.82

Balance Sheet & Liquidity

Debt/Equity
1.77
Quick Ratio
1.44
Current Ratio
2.18
Debt
₹9.29 Cr
Total Assets
₹841.35 Cr
Current Assets
₹556.26 Cr
Working Capital
₹301.33 Cr

Ownership

Promoter Holding
52.20%
Chg in Prom Hold
-
FII / Inst Holding
15.57%
Chg in FII Hold
-0.77%

Financial Snapshot

Enterprise Value
₹9,876.60 Cr
Total Revenue (TTM)
₹1,407.97 Cr
EBITDA
₹456.66 Cr
Free Cash Flow
₹292.48 Cr
Operating Cash Flow
₹337.79 Cr
Shares Outstanding
₹1.66 Cr
Gross Margin
74.07%
Payout Ratio
78.70%

Growth (CAGR)

Revenue 5Y
8.84%
Profit 5Y
19.30%
Revenue (YoY)
19.10%
Earnings (YoY)
54.60%

PROS

  • Strong return on equity of 61.6%.
  • Healthy ROCE of 76.8%.
  • Excellent profit margin of 23.2%.
  • Profit CAGR of 19.3% over 5 years.
  • Attractive dividend yield of 2.56%.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PGHL Procter & Gamble Health Limited NSEPHARMA 6,056.00 30.77 ₹10,052.59 Cr 2.56% 76.81% 61.59% 8.84% 19.30%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --310.99 Cr338.74 Cr324.92 Cr373.86 Cr370.45 Cr
Cost of Revenue --98.72 Cr93.99 Cr68.40 Cr109.82 Cr92.87 Cr
Gross Profit --212.27 Cr244.75 Cr256.52 Cr264.04 Cr277.58 Cr
Operating Expenses --136.72 Cr159.85 Cr142.33 Cr159.48 Cr148.16 Cr
Operating Income --75.55 Cr84.90 Cr114.19 Cr104.56 Cr129.42 Cr
EBITDA --84.03 Cr94.37 Cr125.22 Cr114.82 Cr139.59 Cr
Interest Expense --13.00 L12.00 L12.00 L10.00 L21.00 L
Pretax Income --78.53 Cr88.81 Cr119.02 Cr108.82 Cr133.21 Cr
Tax Provision --17.35 Cr22.63 Cr30.48 Cr31.23 Cr38.61 Cr
Net Income --61.18 Cr66.18 Cr88.54 Cr77.59 Cr94.60 Cr
Diluted EPS --36.8639.8753.5446.7456.99

Profit & Loss (Annual)

Figures in INR.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Revenue -1,092.04 Cr1,205.86 Cr1,129.49 Cr1,407.97 Cr
Cost of Revenue -367.11 Cr392.13 Cr359.49 Cr365.08 Cr
Gross Profit -724.93 Cr813.73 Cr770.00 Cr1,042.89 Cr
Operating Expenses -477.12 Cr517.88 Cr490.89 Cr609.82 Cr
Operating Income -247.81 Cr295.85 Cr279.11 Cr433.07 Cr
EBITDA -280.87 Cr343.07 Cr301.44 Cr474.00 Cr
Interest Expense -42.00 L77.00 L72.00 L55.00 L
Pretax Income -253.37 Cr314.20 Cr273.32 Cr449.86 Cr
Tax Provision -60.85 Cr84.73 Cr72.34 Cr122.95 Cr
Net Income -192.52 Cr229.47 Cr200.98 Cr326.91 Cr
Diluted EPS 107.00116.00138.00121.00-

Compounded Sales Growth

5 Years:8.84%
1 Year:19.10%

Compounded Profit Growth

5 Years:19.30%
1 Year:54.60%

Stock Price Performance

1 Year:+7.68%
6 Months:+5.62%
3 Months:+20.65%
1 Month:+18.45%

Balance Sheet (Annual)

Figures in INR.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Total Assets -888.12 Cr1,101.19 Cr794.36 Cr841.35 Cr
Current Assets -608.04 Cr796.10 Cr524.22 Cr556.26 Cr
Cash & Equivalents -319.40 Cr435.05 Cr238.50 Cr177.24 Cr
Inventory -115.21 Cr134.94 Cr109.11 Cr136.65 Cr
Receivables -83.44 Cr115.71 Cr85.33 Cr164.26 Cr
Total Liabilities -271.63 Cr350.30 Cr256.12 Cr316.80 Cr
Current Liabilities -231.90 Cr303.90 Cr218.91 Cr254.93 Cr
Long Term Debt -----
Total Debt -2.83 Cr12.00 Cr9.56 Cr9.29 Cr
Total Equity -616.49 Cr750.89 Cr538.24 Cr524.55 Cr
Shares Outstanding -1.66 Cr1.66 Cr1.66 Cr1.66 Cr

Cash Flows (Annual)

Figures in INR.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Operating Cash Flow -169.52 Cr236.00 Cr228.29 Cr337.79 Cr
Investing Cash Flow --25.54 Cr-21.50 Cr-6.87 Cr1.26 Cr
Financing Cash Flow --288.63 Cr-98.47 Cr-418.11 Cr-343.92 Cr
Capital Expenditure --37.92 Cr-42.48 Cr-21.73 Cr-15.51 Cr
Free Cash Flow -131.60 Cr193.52 Cr206.56 Cr322.28 Cr
Net Change in Cash --144.65 Cr116.03 Cr-196.69 Cr-4.87 Cr

Ratios (Annual)

Figures in %.

Metric Jun 2021Jun 2022Jun 2023Jun 2024Mar 2026
Gross Margin % -66.4%67.5%68.2%74.1%
Operating Margin % -22.7%24.5%24.7%30.8%
Net Margin % -17.6%19.0%17.8%23.2%
ROE % -31.2%30.6%37.3%62.3%
ROCE % -37.8%37.1%48.5%73.8%

Shareholding Pattern

Insiders
52.20%
Institutions
15.57%
Public Float
32.58%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PGHL

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space